Galmed Pharmaceuticals Ltd. announced a new lipid‑nanoparticle formulation of its SCD1 inhibitor Aramchol that can cross the blood‑brain barrier and be delivered via subcutaneous injection.
The formulation, developed with Barcode Nanotech, demonstrated in vitro activity against α‑synuclein aggregation, a key driver of Parkinson’s disease and other synucleinopathies.
The breakthrough positions Galmed to enter the high‑growth neurodegenerative disease market, potentially creating a disease‑modifying therapy where none currently exist, and diversifying its pipeline beyond non‑alcoholic steatohepatitis.
Galmed’s financials remain modest, with a net loss of $1.1 million in Q1 2025 versus $1.3 million in Q1 2024, and cash and cash equivalents of $20.1 million as of March 31 2025. The company’s market capitalization was $4.11 million on April 9 2026. The new formulation could materially improve the company’s long‑term prospects.
The announcement was met with a significant positive market reaction, reflecting investor enthusiasm for the breakthrough. Management highlighted the potential impact of the new formulation in its statements.
CEO Allen Baharaff said, "Based on our preliminary in‑vitro data which demonstrated that Aramchol dose‑dependently down‑regulated αSyn‑aggregation as well as indicating that the treatment was not associated with toxicity, we believe that treatment with Aramchol could prevent the pathophysiological cascade that leads to αSyn‑aggregation which induces a chronic inflammatory state that is associated with PD disease progression and severity."
Barcode Nanotech co‑founder and CEO Ronen Eavri added, "Barcode Nanotech has developed a library of novel lipids for RNA and DNA, LNP‑based delivery, through a unique in vivo & AI‑based screening platform which allow simultaneously screening of hundreds of different nanoparticle formulations."
Galmed plans to advance the new formulation into proof‑of‑concept Phase 1b/2 studies in Parkinson disease patients in the second half of 2026, subject to regulatory guidance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.